CN115038434A - 用于治疗角膜病变的生物分子 - Google Patents

用于治疗角膜病变的生物分子 Download PDF

Info

Publication number
CN115038434A
CN115038434A CN202080092916.8A CN202080092916A CN115038434A CN 115038434 A CN115038434 A CN 115038434A CN 202080092916 A CN202080092916 A CN 202080092916A CN 115038434 A CN115038434 A CN 115038434A
Authority
CN
China
Prior art keywords
corneal
dha
cornea
eye
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092916.8A
Other languages
English (en)
Chinese (zh)
Inventor
H·巴赞
N·G·巴赞
T·L·彭
B·君
N·A·佩塔西斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
University of Southern California USC
Original Assignee
Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering, University of Southern California USC filed Critical Luis Anna State University Monitoring Committee College Of Agriculture And Mechanical Engineering
Publication of CN115038434A publication Critical patent/CN115038434A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080092916.8A 2019-12-09 2020-12-09 用于治疗角膜病变的生物分子 Pending CN115038434A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945580P 2019-12-09 2019-12-09
US62/945,580 2019-12-09
PCT/US2020/064042 WO2021119146A1 (en) 2019-12-09 2020-12-09 Biomolecule for treatment of corneal pathologies

Publications (1)

Publication Number Publication Date
CN115038434A true CN115038434A (zh) 2022-09-09

Family

ID=76330542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092916.8A Pending CN115038434A (zh) 2019-12-09 2020-12-09 用于治疗角膜病变的生物分子

Country Status (8)

Country Link
US (1) US20230019568A1 (https=)
EP (1) EP4072578A4 (https=)
JP (1) JP2023504205A (https=)
CN (1) CN115038434A (https=)
AU (1) AU2020402031A1 (https=)
BR (1) BR112022011276A2 (https=)
CA (1) CA3161233A1 (https=)
WO (1) WO2021119146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4311554A1 (en) * 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
WO2014032026A1 (en) * 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
CN104684389A (zh) * 2012-05-10 2015-06-03 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018333A2 (en) * 2007-07-30 2009-02-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
US20240041813A1 (en) * 2020-09-10 2024-02-08 Boards of Supervisors of Louisiana State University and Agricultural and Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
CN104684389A (zh) * 2012-05-10 2015-06-03 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
WO2014032026A1 (en) * 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Also Published As

Publication number Publication date
WO2021119146A1 (en) 2021-06-17
AU2020402031A1 (en) 2022-06-30
EP4072578A1 (en) 2022-10-19
JP2023504205A (ja) 2023-02-01
EP4072578A4 (en) 2024-01-10
BR112022011276A2 (pt) 2022-09-06
US20230019568A1 (en) 2023-01-19
CA3161233A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
Phadatare et al. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges
Pinazo-Durán et al. Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders
Chu et al. Inflammation mechanism and anti-inflammatory therapy of dry eye
Aragona et al. Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease
de Paiva et al. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye
Zhang et al. Apigenin protects mouse retina against oxidative damage by regulating the Nrf2 pathway and autophagy
TWI658828B (zh) 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
Galbis-Estrada et al. Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids
Lim et al. Lipid-based therapy for ocular surface inflammation and disease
Zhang et al. Effects of pranoprofen on aqueous humor monocyte chemoattractant protein-1 level and pain relief during second-eye cataract surgery
US10548887B2 (en) Pharmaceutical composition and uses thereof
Aragona et al. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome
Kim et al. Oral hyaluronic acid supplementation for the treatment of dry eye disease: a pilot study
CN105997973A (zh) 用于角膜上皮病变和/或结膜上皮病变的治疗剂或预防剂
EP3151827B1 (en) Methods of treating chronic dry eye disease using c16:1n7 palmitoleate and derivatives thereof
JP2022003042A (ja) 加齢黄斑変性のための高用量スタチン
CN115038434A (zh) 用于治疗角膜病变的生物分子
US20240041813A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
HK40080196A (en) Biomolecule for treatment of corneal pathologies
Babizhayev et al. Novel intraocular and systemic absorption drug delivery and efficacy of N‐acetylcarnosine lubricant eye drops or carcinine biologics in pharmaceutical usage and therapeutic vision care
Layton et al. Monocarboxylate transporter expression remains unchanged during the development of diabetic retinal neuropathy in the rat
Temnik et al. Intravenous 64zn-Aspartate Mitigates Neuroinflammation and Motor Dysfunction in an Lps-Induced Parkinson’s Disease Rat Model
Fahmy et al. Treating ocular surface disease: new agents in development
Chen et al. Partially hydrolyzed guar gum alleviates neurological deficits and gastrointestinal dysfunction in mice with traumatic brain injury

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080196

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220909